Chemomab Therapeutics Ltd
CMMB1.530USD
+0.080+5.52%
終値 02/06, 16:00（ET）15分遅れの株価
37.68M時価総額
損失額直近12ヶ月PER
詳細情報 Chemomab Therapeutics Ltd 企業名
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltdの企業情報
企業コードCMMB
会社名Chemomab Therapeutics Ltd
上場日Aug 14, 2012
最高経営責任者「CEO」Mor (Adi)
従業員数16
証券種類Depository Receipt
決算期末Aug 14
本社所在地Kiryat Atidim, Building 7
都市TEL AVIV-YAFO
証券取引所NASDAQ OMX - NASDAQ BASIC
国Israel
郵便番号6158002
電話番号972773310156
ウェブサイトhttps://www.chemomab.com/
企業コードCMMB
上場日Aug 14, 2012
最高経営責任者「CEO」Mor (Adi)
Chemomab Therapeutics Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-3112.00%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-3112.00%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sat, Jan 31
更新時刻: Sat, Jan 31
株主統計
種類
株主統計
株主統計
比率
Otto (Erik)
6.86%
Apeiron Investment Group Ltd
4.60%
Rivendell Investments 2017-9 LLC
4.50%
Sphera Funds Management Ltd.
2.92%
Morgan Stanley & Co. LLC
1.46%
他の
79.66%
株主統計
株主統計
比率
Otto (Erik)
6.86%
Apeiron Investment Group Ltd
4.60%
Rivendell Investments 2017-9 LLC
4.50%
Sphera Funds Management Ltd.
2.92%
Morgan Stanley & Co. LLC
1.46%
他の
79.66%
種類
株主統計
比率
Individual Investor
9.55%
Family Office
4.60%
Corporation
4.50%
Hedge Fund
3.78%
Research Firm
1.91%
Investment Advisor
1.03%
Investment Advisor/Hedge Fund
0.53%
他の
74.10%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
30
390.31K
17.98%
--
2025Q3
30
390.31K
17.98%
-667.39K
2025Q2
30
1.06M
18.61%
+124.78K
2025Q1
31
932.92K
24.29%
-212.50K
2024Q4
32
1.04M
26.27%
-97.26K
2024Q3
29
1.14M
22.64%
+165.56K
2024Q2
28
668.24K
21.48%
+2.79K
2024Q1
32
666.14K
22.68%
-139.12K
2023Q4
33
705.36K
20.90%
+69.50K
2023Q3
33
635.85K
25.86%
-196.00
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Otto (Erik)
422.50K
6.86%
+133.75K
+46.32%
Aug 11, 2025
Apeiron Investment Group Ltd
283.00K
4.6%
+101.21K
+55.68%
Dec 31, 2024
Rivendell Investments 2017-9 LLC
277.13K
4.5%
--
--
Dec 31, 2024
Sphera Funds Management Ltd.
179.43K
2.92%
-5.09K
-2.76%
Sep 30, 2025
Morgan Stanley & Co. LLC
90.06K
1.46%
-313.47K
-77.68%
Sep 30, 2025
Mor George (Adi)
79.27K
1.29%
--
--
Dec 31, 2024
Ikarian Capital LLC
53.26K
0.87%
-1.00
-0.00%
Sep 30, 2025
George (Kobi)
50.06K
0.81%
-12.73K
-20.27%
Dec 31, 2024
Cohen (Neil Harris)
35.30K
0.57%
-2.50K
-6.61%
Dec 31, 2024
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Aug 08, 2025
Merger
4→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
日付
配当落ち日
種類
比率
Aug 08, 2025
Merger
4→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
